IP Library Granted Patent US 12,209,107
Granted Patent B2
US 12,209,107 · App. 16/822,385 · Granted Jan 28, 2025

Process for preparing high puritiy allopregnanolone and intermediates thereof

Inventors: Ivano Messina (Valladolid, ES); Jesús Miguel Iglesias Retuerto (Valladolid, ES); Ana María Ares Sacristán (Valladolid, ES)
Assignee: CRYSTAL PHARMA, S.A.U.
C07J9/00C07J7/009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,107
App. No.
16/822,385
Granted
Jan 28, 2025
Kind
B2
Abstract

The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.

Claims (22)

1. A chromatography-free process for preparing allopregnanolone which comprises:

reacting isoallopregnanolone with a strong carboxylic acid having a pKa≤3 under suitable Mitsunobu conditions, thereby obtaining a 3-carboxylic ester of allopregnanolone;

precipitating the 3-carboxylic ester of allopregnanolone in a solvent system comprising water and an organic solvent;

purifying the precipitate of the 3-carboxylic ester of allopregnanolone by recrystallizing in a non-polar solvent; and

subjecting the purified 3-carboxylic ester of allopregnanolone to hydrolysis, thereby obtaining allopregnanolone.

2. The process according to claim 1 , wherein the hydrolysis occurs under (i) neutral conditions, (ii) mild basic conditions by treatment with a base whose conjugate acid has a pKa≤11, or (iii) energetic basic conditions by treatment with a base whose conjugate acid has a pKa≥12.

3. The process according to claim 1 , wherein the strong carboxylic acid is selected from the group consisting of mono-, di-, and trifluoroacetic acid, mono-, di-, and trichloroacetic acid, cyanoacetic acid, and ortho-nitrobenzoic- and dinitrobenzoic acid.

4. The process according to claim 1 , wherein the 3-carboxylic ester of allopregnanolone is precipitated in a solvent system comprising water and a water-soluble organic solvent.

5. The process according to claim 1 , wherein the 3-carboxylic ester of allopregnanolone is precipitated in a solvent system comprising water and a water-soluble organic solvent selected from 1,4-dioxane, acetone, acetonitrile, DMF, methanol, ethanol, isopropanol, and mixtures thereof,

and/or

the precipitate of the 3-carboxylic ester of allopregnanolone is recrystallized in a non-polar solvent selected from group consisting of hexane, cyclohexane, heptane, toluene, iPr 2 O, MeOtBu, and mixtures thereof.

6. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis under neutral conditions with an alcohol without adding any acid or base.

7. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis with a base whose conjugate acid has a pKa≤11.

8. The process according to claim 7 , wherein the base whose conjugate acid has a pKa≤11 is an alkali or alkaline earth carbonate or bicarbonate.

9. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis with a base whose conjugate acid has a pKa≥12 for a time and at a temperature suitable to keep the level of 3α-hydroxy-5α,17α-pregnan-20-one in an amount of 0.5% or less.

10. The process according to claim 9 , wherein the base whose conjugate acid has a pKa≥12 is an alkali or alkaline earth C 1-6 alkoxide or hydroxide.

11. The process according to claim 9 , wherein the hydrolysis is carried out for not more than about 2 h and/or at a temperature of about 15-40° C.

12. The process according to claim 1 , wherein following precipitation and recrystallization, the allopregnanolone has a total content of 5α-pregn-2-en-20-one and 3α-hydroxy-5α,17α-pregnan-20-one of about 0.15% or below.

13. The process according to claim 2 , wherein the hydrolysis under energetic basic conditions is carried out for not more than about 2 h and/or at a temperature of about 15-40° C.

14. The process according to claim 1 , wherein the suitable Mitsunobu conditions comprise use of at least one phosphine, at least one azodicarboxylate, and optionally a tertiary amine additive, wherein the at least one phosphine is selected from the group consisting of triphenyl phosphine, dicyclohexylphenylphosphine, diethylphenylphosphine, tributylphosphine, diphenyl-2-pyridylphosphine, 4-(dimethylamino) phenyldiphenylphosphine, isopropyldiphenylphosphine, tri-tert-butylphosphine, tri-n-octylphosphine, tricyclohexylphosphine, polystyryldiphenylphosphine, and a mixture thereof, and wherein the at least one azodicarboxylate is selected from the group consisting of diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), di-t-butyl azodicarboxylate, 1,1′-(azocarbonyl) dipiperidine, dibenzyl azodicarboxylate, and a mixture thereof.

15. The process according to claim 1 , wherein the purified 3-carboxylic ester of allopregnanolone contains an amount of 5α-pregn-2-en-20-one of about 0.5% or less.

16. The process according to claim 5 , wherein the ratio of water to water-soluble organic solvent is about 0.2:1 to 1:0.2.

Assignments (4)
CHANGE OF NAME Recorded Nov 5, 2025
From: CRYSTAL PHARMA, S.A.U.
To: CURIA SPAIN, S.A.U.
Reel/Frame 073449/0630 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 054320 FRAME: 0125. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 17, 2020
From: BIONICE, S.L.U
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 054702/0748 →
MERGER Recorded Nov 10, 2020
From: BIONICE, S.L.U
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 054320/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2020
From: MESSINA, IVANO; IGLESIAS RETUERTO, JESUS MIGUEL; ARES SACRISTAN, ANA MARIA
To: BIONICE, S.L.U.
Reel/Frame 052699/0389 →